ESMO 17 th World Congress on Gastrointestinal Cancer, page-8

First 8 Last

Share
Profile

Follow
kashmirz

128 Posts.

19/06/15

13:11

Post #: 15496664
Share

Originally posted by cafa ↑

Wild
'Chatting to an oncology colleagues who attended ASCO, there remains some skepticism amongst some attendees regarding the clinical significance of the SIRFLOX findings given no oPFS benefit and the entrenched view that cancer is a systemic disease. Attitude seems to be to treat with chemo first and use SIRT if progression occurs. '

I'm not a specialist in cancer spread, so excuse me if my understanding is incorrect. My thought was that colon cancer hits the liver first, due to the blood supply, and then spreads to other organs.

If colon cancer can be caught very early then there is a much smaller chance of spreading to other organs. Once it spreads to the liver then the chances of spreading to other organs stats to go up, depending on the length of time in the liver.

Thus early resection of mCRC is the preferred option. One assumes that by the time resection is no longer an option there must be a much higher chance of addition organs being impacted.

At this point it now comes down to how best to manage the situation. If, and I think there is very open views, 90% of deaths are caused by the liver cancer then by extending the PFS in the liver it allows said additional time to manage the other organs.

I believe that death from cancer in the other organs can be extended by some years in most cases.

Thus I'm not understanding the view of the oncologists that you speak to. I would have thought that SIRT being used early to give the additional time to manage the other mets would be seen as a very good option.

I guess we find out in Feb when the 6 month dose sales are presented.

Expand

cafa, wild,, there are a range of views among clinicians:
http://www.medscape.com/viewarticle/846248

Brandon G. Smaglo, MD
June 12, 2015

"median PFS in the liver was significantly and impressively extended in the SIRT arm: PFS was 20.5 months in the SIRT arm vs 12.6 months in the control arm. The OS data are still maturing, but it would be surprising if this robust 8-month improvement in PFS did not to translate into an OS benefit."

SRX Price at posting: $29.78 Sentiment: Buy Disclosure: Held
Upvote

0 Great analysis

Reply

Top Stories

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

BCI

BCI reaches close of funding facility for salt-first part of Mardie project

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation